tiprankstipranks
Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
The Fly

Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M

Backs FY24: Anticipated Operating Expenses expected to remain between $115 million and $120 million; Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App